Healthcare Industry News: Cytori Therapeutics
News Release - November 14, 2006
Enrollment Completed Utilizing Cytori's Adipose-Derived Stem Cell Technology for Treatment of Breast Cancer ComplicationsLead Investigator Reports Preliminary Observations of Safety and Feasibility
FUKUOKA, Japan--(HSMN NewsFeed)--Cytori Therapeutics, Inc. (NASDAQ: CYTX ; Frankfurt: XMPA ) was informed of the completion of enrollment of the 11 patient investigator-initiated RESTORE study in Japan using adipose-derived stem cells to treat the complications of surgery and radiation damage following partial mastectomy for the treatment of breast cancer. The administered cells were extracted and concentrated from the patients' own adipose tissue using Cytori's stem cell processing system.
"In the first 11 patients, clinical follow up indicates that the therapy is safe and well tolerated," said Keizo Sugimachi, M.D., lead investigator and President, Kyushu Central Hospital. "It appears that adipose-derived stem cells can treat the side effects of surgery and radiation therapy, which includes breast disfigurement, tissue loss, pain and other complications of cancer treatment. The stem cells, which were extracted and processed using Cytori's technology, appear to improve the outcome of these patients."
"We are highly encouraged by this report," said Marc Hedrick, M.D., President of Cytori Therapeutics. "Based on this information, Cytori intends to sponsor a formal clinical study to further assess the potential for adipose-derived stem cells in this field and to support market adoption and reimbursement for this significant unmet medical need."
More than one million women worldwide are diagnosed with breast cancer annually, which can often result in significant skin damage and tissue loss. Fortunately, early detection has served to increase the number of women eligible for partial mastectomy. However, this group of women has few if any options for reconstructive surgery.
About Cytori Therapeutics
Cytori Therapeutics, Inc., (NASDAQ: CYTX ; Frankfurt: XMPA ) is discovering and developing cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's investigational products target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary adipose stem cell processing system to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system in an investigational device and has not been approved for use in the above indication.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and prospects of our business which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses and expected continuing losses, the need for further financing, our ability to develop and commercialize regenerative cell-based therapies, our dependence on third parties, our ability to obtain, defend and enforce our intellectual property, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2005 and subsequent SEC filings, which will be available through our web site. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Source: Cytori Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.